Dr Jonathan Coates (Chief Scientific Officer)

Dr Coates obtained his Ph D from Glasgow University and has more than 24 years experience in antiviral drug discovery in the pharmaceutical industry. He spent 15 years in the UK at Glaxo Group Research and later Glaxo-Wellcome, where he filled various senior research roles and was one of the inventors of the anti-viral drug 3TC (Epivir for HIV and Zeffix for HBV). Dr Coates has extensive experience in leading program teams towards successful milestones, including clinical trials and three marketed drugs. Dr Coates joined Amrad Corporation in 1996 to establish a team to develop treatments for infectious diseases. Dr Coates now holds the position of Avexa's Chief Scientific Officer.